There was a big difference between looking like you have money and actually having money.
Bad Decisions Have Consequences.No money whatsoever.
You can even sell the package of shares and then a big zero. No money no funny!
Please, act quickly otherwise it's too late.
The company had a little over $5.3 million in cash at last count (March 31) and runs at a burn of more than $3 million a quarter. Factor in the advancing of two candidates into pivotal trials near term, and even when we include a $1.7 million injection based on the the sale of 1.1 million shares of common stock to Aspire LLC, there’s practically nothing in the bank before the year draws to a close. This means a capital raise, and this in turn probably means dilution.
Food and Drug Administration (FDA) members regarding the Novo Nordisk A/S (NYSE:NVO) anti-diabetic molecule IDegLira’s study design, FDA Endocrinology and Metabolic Drug Advisory Committee has given approval with a ratio of 16/0.
The drug is indicated for the treatment of diabetes mellitus (DM) type 2 in combo formulation with GLP-1 agonist Victoza (liraglutide) and Tresiba (degludec).
IDegLira is a combination formulation targeting type 2 diabetes effectively. The clinical studies have proved that one of the both drugs can easily control a higher level of the blood sugar rather, making the second drug useless for the patient.
In the case of an approval, the drug would be the first combination formulation with a fixed ratio in a single injection.
and I repeat approval with a ratio of 16/0 !!!
One Cellceutix Phase III is about to begin (ABSSSI). Two Phase IIs are underway (psoriasis and oral mucositis). And one Phase I recently completed (advanced solid tumors). Additional Phase II trials have been announced and are in planning stages, most recently ulcerative proctictis. The company also has received numerous FDA expedited and other special designations across its entire platform, including: Qualified Infectious Disease Product (skin infections); Fast Track (oral mucositis); Orphan Drug (ovarian cancer); Orphan Drug (pancreatic cancer); Orphan Drug and Rare Pediatric Disease (retinoblastoma). Special Protocol Assessment (ABSSSI) designation may be the next feather in its cap.
Brilacidin received Qualified Infectious Disease Product (QIDP) designation via the GAIN Act, qualifying it for Fast Track and Priority Review, and an extra 5 years of market exclusivity.
Given Brilacidin's unique mechanism-of-action (piercing bacterial walls), antimicrobial resistance is less likely (less quickly) to develop. Brilacidin already has performed on par with current best-in-class, Cubicin (Daptomycin), as shown in a Phase IIb trial.
Additional discovery efforts are underway, in partnership with researchers at Fox Chase Medical Center, to design Brilacidin analogs (CC-1807) that are active against gram-negative bacteria-Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and ndm-1-producing K. pneumoniae-as well as anti-fungals active against Candidiasis (CC-1502) common to the oral cavity.
Brilacidin was mentioned in this February 2016 article--"Companies Take Aim at MRSA Infections"--as a new first-in-class antibiotic "expected to succeed." Another recent study (published in October 2015), aptly titled, "Membrane-Active Small Molecules: Designs Inspired by Antimicrobial Peptides," also highlights Brilacidin, reinforcing Zasloff's assessment: "The future of small-molecule membrane-active agents is very bright."
negative - 10 % CTIC
negative- 24% CTIC
negative- 124% CTIC
negative- 1126% CTIC
negative- 10346% CTIC
negative- 107237 % CTIC
negative- 10002356% CTIC
And now it's all right, it's ok
And you may look the other way
We can try to understand
You're stayin' alive, stayin' alive
Feel the city breakin' and everybody shakin'
It’s not going to be a tragedy of the Euro Carolyn Brexit would be an opportunity not a tragedy.
One less hungry mouth at the family table.
The big question is Money. Cash and Cash equivalents were down this period to 5.34 million compared to 10.80 million in the same period last year.
Findings from a phase 3a clinical trial for semaglutide, an examinational glucagon-like peptide-1 (GLP-1) analogue, demonstrated that treatment with semaglutide, administered once-weekly, importantly improved glycemic control compared to insulin glargine U100 in adults with type 2 diabetes.
The 30-week SUSTAIN 4 trial showed that, from a mean baseline HbA1c of 8.2%, adults with type 2 diabetes receiving metformin with or without sulfonylurea, achieved statistically important and superior improvements in HbA1c reductions of 1.2% and 1.6% when treated with 0.5 mg and 1.0 mg semaglutide, respectively, vs a 0.8% reduction with insulin glargine U100 (p. More adults treated with 0.5 mg and 1.0 mg semaglutide achieved HbA1c targets compared with insulin glargine U100. HbA1c As concerns of stock price volatility, it was 1.19% for a week and 1.21% for a month.
Savara Pharmaceuticals AeroVanc pulmonary Phase 2
Cardeas Pharma Amikacin + fosfomycin pulmonary Phase 2
Bayer Amikacin Inhale pulmonary Phase 3
Insmed Pharmaceuticals Arikayce pulmonary Phase 3
Allergan Avarofloxacin systemic Phase 2
Nabriva Therapeutics BC-3781 systemic Phase 3
Microbion Corporation BisEDT Antimicrobial Gel topical Phase 1
Cellceutix Pharmaceuticals Brilacidin systemic Phase 2
Actelion Pharmaceuticals Cadazolid GI only Phase 3
Allergan Ceftazidime + avibactam systemic Approved US
Basilea Pharmaceutica Ceftobiprole systemic Phase 3
Merck Ceftolozane + tazobactam systemic Approved US
Aradigm Pharmaceuticals Ciprofloxacin pulmonary Phase 3
Bayer HealthCare Ciprofloxacin DPI pulmonary Phase 3
Innocoll AG Cogenzia topical Phase 3
Durata Therapeutics Dalbavancin systemic Approved US
Debiopharm Pharmaceuticals Debio-1450 systemic Phase 2
Debiopharm Pharmaceuticals Debio-1452 systemic Phase 2
Melinta Therapeutics Delafloxacin systemic Phase 3
Tetraphase Pharmaceuticals Eravacycline systemic Phase 3
Entasis ETX-0914 systemic Phase 2
MerLion Pharmaceuticals Finafloxacin systemic Phase 2
Cempra Pharmaceuticals Fusidic Acid systemic Phase 3
GlaxoSmithKline plc GSK-2140944 systemic Phase 2
Motif Bio Iclaprim systemic Phase 3
Merck & Co., Inc. Imipenem/cilastatin + MK-7655 systemic Phase 3